Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer

Nilsson, Jonas; Skog, Johan; Nordstrand, Annika; Baranov, Vladimir; Mincheva‐Nilsson, Lucia; Breakefield, Xandra O.; Widmark, Anders

doi:10.1038/sj.bjc.6605058

Cited by 695 publications

(560 citation statements)

References 18 publications

Supporting

Mentioning

533

Contrasting

Unclassified

Order By: Relevance

“…It is possible to detect the mRNA of two molecules known to be overexpressed in prostate cancer, PCA3 and a specific product resulting from a chromosomal rearrangement, the TMPRSS2:ERG fusion [55]. Also aquaporin 1 and 2 as markers of renal ischemia/reperfusion injury or anti diurectic hormone action respectively [56], have been characterized.…”

Section: Exosome As Biomarkers Of Pathologiesmentioning

confidence: 99%

Exosomes as intercellular signalosomes and pharmacological effectors

Record

Subra

Silvente-Poirot

et al. 2011

Biochemical Pharmacology

475

336

View full text Add to dashboard Cite

International audienceCell secretion is a general process involved in various biological responses. Exosomes are part of this process and have gained considerable scientific interest in the past five years. Several steps through investigations across the last 20years can explain this interest. First characterized during reticulocyte maturation, they were next characterized as a key player in the immune response and cancer immunotherapy. More recently they were characterized as vectors of mRNAs, miRNAs and also lipid mediators able to act on target cells. They are the only type of vesicles released from an intracellular compartment from cells in viable conditions. They appear as a vectorized signaling system operating from inside a donor cell towards either the periphery, the cytosol, or possibly to the nucleus of target cells. Exosomes from normal cells trigger positive effects, whereas those from pathological ones, such as tumor cells or infected ones may trigger non-positive health effects. Therefore regulating the biogenesis and secretion of exosomes appear as a pharmacological challenge to intervene in various pathophysiologies. Exosome biogenesis and molecular content, interaction with target cells, utilisation as biomarkers, and functional effects in various pathophysiologies are considered in this review

show abstract

Section: Exosome As Biomarkers Of Pathologiesmentioning

confidence: 99%

Exosomes as intercellular signalosomes and pharmacological effectors

Record

Subra

Silvente-Poirot

et al. 2011

Biochemical Pharmacology

475

336

View full text Add to dashboard Cite

show abstract

“…In addition to studies showing that EVs are characterized by specific membrane proteins,29 the nucleic acid contents of C‐EVs in the plasma/serum from malignant tumor patients are also markedly different than those from healthy controls, indicating that the specific nucleic acid content in C‐EVs should be the focus of greater attention in the search for new tumor biomarkers 30, 31. Recently, EVs have come to be considered effective diagnostic and predictive tools for patients suffering from malignant tumors, such as breast and prostate cancers 32, 33. In addition to tumors, EVs show potential in the diagnosis of infectious diseases and even in the assessment of disease progression 34, 35, 36…”

Section: Introductionmentioning

confidence: 99%

Modularized Extracellular Vesicles: The Dawn of Prospective Personalized and Precision Medicine

2018

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are ubiquitous nanosized membrane vesicles consisting of a lipid bilayer enclosing proteins and nucleic acids, which are active in intercellular communications. EVs are increasingly seen as a vital component of many biological functions that were once considered to require the direct participation of stem cells. Consequently, transplantation of EVs is gradually becoming considered an alternative to stem cell transplantation due to their significant advantages, including their relatively low probability of neoplastic transformation and abnormal differentiation. However, as research has progressed, it is realized that EVs derived from native‐source cells may have various shortcomings, which can be corrected by modification and optimization. To date, attempts are made to modify or improve almost all the components of EVs, including the lipid bilayer, proteins, and nucleic acids, launching a new era of modularized EV therapy through the “modular design” of EV components. One high‐yield technique, generating EV mimetic nanovesicles, will help to make industrial production of modularized EVs a reality. These modularized EVs have highly customized “modular design” components related to biological function and targeted delivery and are proposed as a promising approach to achieve personalized and precision medicine.

show abstract

“…There are studies regarding exosome analysis of plasma [197], urine [198], amniotic fluid [199], saliva [200], bronchoalveolar lavage fluid [201], breast milk [202] etc.…”

Section: Extracellular Vesicles -Future Perspectivesmentioning

confidence: 99%